Leif Niclas Fredrik Löwgren
Director/Board Member chez Omnivation AB
Profil
Leif Niclas Fredrik Löwgren is currently a Director at Omnivation AB.
He was previously a Director at Copperstone Resources AB, QuiaPEG Pharmaceuticals AB, NextCell Pharma AB, and Quiapeg Pharmaceuticals Holding AB.
Mr. Löwgren holds an MBA from the University of Stockholm.
Postes actifs de Leif Niclas Fredrik Löwgren
| Sociétés | Poste | Début |
|---|---|---|
| Omnivation AB | Director/Board Member | - |
Anciens postes connus de Leif Niclas Fredrik Löwgren
| Sociétés | Poste | Fin |
|---|---|---|
| COPPERSTONE RESOURCES AB | Director/Board Member | 14/05/2019 |
| NEXTCELL PHARMA AB | Director/Board Member | - |
| QUIAPEG PHARMACEUTICALS HOLDING AB | Director/Board Member | - |
QuiaPEG Pharmaceuticals AB
 QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Director/Board Member | - |
Formation de Leif Niclas Fredrik Löwgren
| University of Stockholm | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| COPPERSTONE RESOURCES AB | Non-Energy Minerals |
| NEXTCELL PHARMA AB | Health Technology |
| QUIAPEG PHARMACEUTICALS HOLDING AB | Health Technology |
| Entreprise privées | 2 |
|---|---|
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Health Technology |
| Omnivation AB |
